Skip to main content

Advertisement

SpringerLink
Log in

ErbB1–ErbB4 nuclear and cytoplasmic overexpression, ethnicity and predicted outcome in prostate cancer

  • Original Research
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Few inconclusive studies are reported on ErbB1–ErbB4 overexpression in prostate cancer. The goal of this study is to evaluate ErbB1–ErbB4 nuclear and cytoplasmic expression in prostate cancer patients and to correlate it to the patients’ ethnicity and outcome. T-stage, Gleason score, pre-treatment prostate-specific antigen (PSA) levels and ethnicity were recorded in 50 patients. Ethnicity was defined as either Ashkenazic (immigrated from Europe or North America) or Sephardic origin (Middle East and North Africa). Kattan nomogram was used to predict 5-year progression-free probability (PFP). ErbB1–ErbB4 nuclear and cytoplasmic expression were evaluated by immuno-histochemistry staining. The Ashkenazic (n = 27) and Sephardic (n = 23) patients were comparable in age, T stage, PSA level and Gleason score. ErbB1 cytoplasmic overexpression was found in 66% and none had nuclear overexpression. ErbB2 overexpression was not found in all patients. ErbB3 overexpression was seen in 5%. ErbB4 cytoplasmic and nuclear overexpression was seen in 28% and in 30% to a total of 38%. The ErbB1 and ErbB4 in the Ashkenazic and Sephardic patients were 65, 67, 34 and 44% respectively. PFP of >80%, 60–80% and <60% were seen in 55, 34, and 11% respectively. Ethnicity and overexpression did not significantly contributed to the PFP. In conclusion, ErbB1 and ErbB4 overexpression was seen in 66% and in 38% of prostate cancer patients, while ErbB2 and ErbB3 were almost not overexpressed in prostate cancer patients. Neither overexpression nor ethnicity significantly contributed to the predicted outcome. Further studies on ErbB expression, ethnicity and outcome in prostate cancer patients are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barton J, Blackledge G, Wakeling A et al (2001) Growth factors and their receptors: new targets for prostate cancer therapy. Urology 58:114–122

    Article  PubMed  CAS  Google Scholar 

  2. Di Lorenzo G, Tortora G, D’Armiento FP et al (2002) Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8:3438–3444

    PubMed  Google Scholar 

  3. Gil-Diez de Medina S, Salomon L, Colombel M et al (1998) Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum Pathol 29:1005–1012

    Article  PubMed  CAS  Google Scholar 

  4. Moul JW, Maygarden SJ, Ware JL et al (1996) Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. J Urol 155:982–985

    Article  PubMed  CAS  Google Scholar 

  5. Scher HI, Sarkis A, Reuter V et al (1995) Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1:545–550

    PubMed  CAS  Google Scholar 

  6. Mellon K, Thompson S, Charlton RG et al (1992) p53,c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 147:496–499

    PubMed  CAS  Google Scholar 

  7. Kuhn EJ, Kurnot RA, Sesterhenn IA et al (1993) Expression of the c-erbB-2 (HER-2/neu)oncoprotein in human prostatic carcinoma. J Urol 150:1427–1433

    PubMed  CAS  Google Scholar 

  8. Fossa A, Lilleby W, Fossa SD et al (2002) Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy. Int J Cancer 99:100–105

    Article  PubMed  CAS  Google Scholar 

  9. Osman I, Scher HI, Drobnjak M et al (2001) HER-2/neu (p185neu)protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 7:2643–2647

    PubMed  CAS  Google Scholar 

  10. Reese DM, Small EJ, Magrane G et al (2001) HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 116:234–239

    Article  PubMed  CAS  Google Scholar 

  11. Signoretti S, Montironi R, Manola J et al (2002) Her-2-neu expression and progression toward androgen independence inhuman prostate cancer. J Natl Cancer Inst 92:1918–1925

    Article  Google Scholar 

  12. Savinainen KJ, Saramaki OR, Linja MJ et al (2002) Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 160:339–445

    PubMed  CAS  Google Scholar 

  13. Hernes E, Fossa SD, Berner AA et al (2004) Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen independence. Br J Cancer 90:449–454

    Article  PubMed  CAS  Google Scholar 

  14. Ni CY, Murphy MP, Golde TE et al (2001) Gamma-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294:2179–2181

    Article  PubMed  CAS  Google Scholar 

  15. Lo HW, Xia W, Wei Y et al (2005) Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 65:338–348

    PubMed  CAS  Google Scholar 

  16. Rebbeck TR (2005). Genetics, disparities, and prostate cancer. LDI Issue Brief 10:1. http://www.upenn.edu/ldi/issuebrief10_7.pdf. Accessed 19 Nov 2007

  17. Whittemore AS, Cirillo PM, Feldman D et al (2005) Prostate-specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J Urol 174:872–876

    Article  PubMed  Google Scholar 

  18. Kattan MW, Zelefsky MJ, Kupelian PA et al (2003) Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 21:4568–4571

    Article  PubMed  Google Scholar 

  19. Canil CM, Moore MJ, Winquist E et al (2005) Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23:455–460

    Article  PubMed  CAS  Google Scholar 

  20. Ziada A, Barqawi A, Glode LM et al (2004) The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60:332–337

    Article  PubMed  CAS  Google Scholar 

  21. Lara PN Jr, Chee KG, Longmate J et al (2004) Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100:2125–2131

    Article  PubMed  CAS  Google Scholar 

  22. Ben-Yosef R, Starr A, Karaush V et al (2007) ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy. Prostate 67:871–880

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Esther Eshkol is to be thanked for language editing.

Conflict of interest statement

No funds were received to support this study.

Author information

Authors and Affiliations

  1. Divisions of Oncology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

    R. Ben-Yosef, D. Sarid, A. Vexler, I. Barnea & N. Yaal Hachoshen

  2. Divisions of Urology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

    G. Lidawi

  3. Divisions of Pathology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

    S. Marmor & A. Stavesky

  4. Divisions of Pulmonology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

    A. Starr

  5. Radiotherapy Institute, Division of Oncology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, 64239, Israel

    R. Ben-Yosef

Authors
  1. R. Ben-Yosef
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Sarid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Vexler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Lidawi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Barnea
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Marmor
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Stavesky
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Starr
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N. Yaal Hachoshen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Ben-Yosef.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ben-Yosef, R., Sarid, D., Vexler, A. et al. ErbB1–ErbB4 nuclear and cytoplasmic overexpression, ethnicity and predicted outcome in prostate cancer. Targ Oncol 3, 13–17 (2008). https://doi.org/10.1007/s11523-007-0069-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-007-0069-y

Keywords

Search

Navigation